Pathology-Free Patient-Specific Baseline

• Pathology-free patient-specific baselines are rigorously defined individual references representing the normal state for a target biological system or imaging modality.
• They are constructed using curated cohorts, generative methods (e.g., GANs, diffusion models), and causal inference to isolate true-negative benchmarks in diagnostic evaluations.
• This approach underpins model specificity, supports personalized disease modeling, and enhances clinical decision-making by distinguishing genuine pathology from benign variations.

A pathology-free patient-specific baseline is a rigorously defined, individualized reference standard representing the normal or healthy state of a subject with respect to a target biological system or imaging modality. In contemporary computational medicine and machine learning for biomedical imaging, such baselines are critical for quantifying abnormality, guiding feature selection, calibrating predictive specificity, and enabling interpretable decision making at the individual patient level. These references can be constructed from curated cohorts (e.g., truly “normal” patients), semi-parametric generative models incorporating genetic and clinical indicators, causal inference frameworks, or learned synthesis methods (GANs, diffusion models) that reconstruct anatomy while selectively erasing pathology. The pathology-free baseline stands as a methodological cornerstone for robust rare-disease detection, evaluation of predictive models, and personalized disease modeling in translational research.

1. Conceptual Foundations and Formal Definitions

The concept of a pathology-free patient-specific baseline arises from the need to precisely distinguish non-target abnormalities from genuine pathology in heterogeneous and imbalanced clinical settings. In the context of model evaluation, Raythatha et al. explicitly construct a “pathology-free” cohort—patients with neither target disease (e.g., bowel injury) nor any other abnormal findings—as a pure negative class for benchmarking specificity (Raythatha et al., 10 Feb 2026). The specificity observed in this group constitutes the maximal achievable true-negative rate when confounding pathologies are absent. This model-agnostic “false positive ceiling” isolates the inherent behavior of a classification or detection framework, free from negative-class heterogeneity.

Generative approaches define the pathology-free baseline as a latent or reconstructed healthy state of the patient given available data. For instance, Dalca et al. employ a semi-parametric model predicting each subject’s anatomically normal trajectory conditioned on baseline imaging, genetics, and clinical data, producing a personalized healthy anatomical projection (Dalca et al., 2020). Causal inference methodologies, as in Strobl & Lasko, identify the healthy baseline as the state where exogenous shocks (“errors” in a structural equation model) revert to typical control values, quantifying deviations as root causes of individual disease expression (Strobl et al., 2022).

2. Negative-Class Baseline in Model Evaluation

Establishing a pathology-free, patient-specific baseline is essential for evaluating specificity under controlled conditions. In Raythatha et al., a group of 50 patients from the RSNA Abdominal Trauma CT dataset, strictly free of target and secondary pathologies, defines the pure-negative reference for traumatic bowel injury detection (Raythatha et al., 10 Feb 2026). The observed specificity on this cohort serves as a baseline (“false-positive ceiling”), against which the impact of increasing negative-class complexity (e.g., presence of solid-organ injury) can be isolated.

Model-specific baseline specificities illustrate this:

Model	Specificity (No Pathology)
RadDINO	100.0%
MedCLIP	84.0%
CNN Baseline	96.0%
Swin Transformer	100.0%
Team Oxygen Ensemble	100.0%

Comparing these values to results on confounded subgroups quantifies specificity loss due to negative-class heterogeneity, a key diagnostic of model robustness in rare-disease detection (Raythatha et al., 10 Feb 2026).

3. Generative and Predictive Modeling of Subject-Specific Pathology-Free Baselines

Semi-parametric and generative models offer alternative constructions of individualized healthy baselines. Dalca et al. formulate a mixed-effects model in which the predicted healthy anatomy at time $t$ is given by

$$y_t = y_b + \Delta x_t\left[\bar\beta + \sum_{j=1}^N \alpha_{G,j} K_G(g, g_j) + \sum_{j=1}^N \alpha_{C,j} K_C(c, c_j) + \sum_{j=1}^N \alpha_{I,j} K_I(f_b, f_{b,j})\right] + \epsilon$$

with $y_b$ the baseline phenotype, $(g, c, f_b)$ representing genetics, clinical features, and baseline imaging PCs, respectively. Thus, a “healthy trajectory”—individualized by multi-modal data—serves as a patient-specific baseline, against which deviations in follow-up scans highlight disease progression (Dalca et al., 2020).

In patient-specific radiomics, reconstructed healthy “personas” are generated for each ROI using dedicated mask-inpainting diffusion models (DDPMs), yielding blended images $$x^{\mathrm{persona}} = M \odot \hat{x} + (1-M) \odot x$$ where $\hat{x}$ is the inpainted output and $M$ the mask (Chen et al., 17 Mar 2025, Chen et al., 13 Jan 2026). Radiomic features extracted from both the original ($x$) and persona images ($x^{\mathrm{persona}}$) jointly provide baseline and deviation features for downstream interpretable classification.

4. Pathology-Free Baselines in Causal and Statistical Inference

A contrasting approach leverages causal graphical models to infer patient-specific, pathology-free baselines in feature space. Strobl & Lasko model observed variables $X$ and diagnosis $$y_t = y_b + \Delta x_t\left[\bar\beta + \sum_{j=1}^N \alpha_{G,j} K_G(g, g_j) + \sum_{j=1}^N \alpha_{C,j} K_C(c, c_j) + \sum_{j=1}^N \alpha_{I,j} K_I(f_b, f_{b,j})\right] + \epsilon$$0 via a linear non-Gaussian acyclic model (LiNGAM):

$$y_t = y_b + \Delta x_t\left[\bar\beta + \sum_{j=1}^N \alpha_{G,j} K_G(g, g_j) + \sum_{j=1}^N \alpha_{C,j} K_C(c, c_j) + \sum_{j=1}^N \alpha_{I,j} K_I(f_b, f_{b,j})\right] + \epsilon$$1

Setting each exogenous error $$y_t = y_b + \Delta x_t\left[\bar\beta + \sum_{j=1}^N \alpha_{G,j} K_G(g, g_j) + \sum_{j=1}^N \alpha_{C,j} K_C(c, c_j) + \sum_{j=1}^N \alpha_{I,j} K_I(f_b, f_{b,j})\right] + \epsilon$$2 to its control-average $$y_t = y_b + \Delta x_t\left[\bar\beta + \sum_{j=1}^N \alpha_{G,j} K_G(g, g_j) + \sum_{j=1}^N \alpha_{C,j} K_C(c, c_j) + \sum_{j=1}^N \alpha_{I,j} K_I(f_b, f_{b,j})\right] + \epsilon$$3 reconstructs the “healthy” baseline configuration $$y_t = y_b + \Delta x_t\left[\bar\beta + \sum_{j=1}^N \alpha_{G,j} K_G(g, g_j) + \sum_{j=1}^N \alpha_{C,j} K_C(c, c_j) + \sum_{j=1}^N \alpha_{I,j} K_I(f_b, f_{b,j})\right] + \epsilon$$4, reflecting the expected state in the absence of disease-related shocks. Deviations $$y_t = y_b + \Delta x_t\left[\bar\beta + \sum_{j=1}^N \alpha_{G,j} K_G(g, g_j) + \sum_{j=1}^N \alpha_{C,j} K_C(c, c_j) + \sum_{j=1}^N \alpha_{I,j} K_I(f_b, f_{b,j})\right] + \epsilon$$5 are assigned sample-specific Shapley value scores $$y_t = y_b + \Delta x_t\left[\bar\beta + \sum_{j=1}^N \alpha_{G,j} K_G(g, g_j) + \sum_{j=1}^N \alpha_{C,j} K_C(c, c_j) + \sum_{j=1}^N \alpha_{I,j} K_I(f_b, f_{b,j})\right] + \epsilon$$6 as quantitative measures of variable-level disease causality for the individual, making the method sensitive to subject-level heterogeneity (Strobl et al., 2022).

5. Generative Pseudo-Healthy Synthesis and Adversarial Models

Generative adversarial frameworks operationalize pathology-free baseline synthesis by explicitly disentangling healthy anatomy from disease. The PathoSyn framework formulates an additive decomposition $$y_t = y_b + \Delta x_t\left[\bar\beta + \sum_{j=1}^N \alpha_{G,j} K_G(g, g_j) + \sum_{j=1}^N \alpha_{C,j} K_C(c, c_j) + \sum_{j=1}^N \alpha_{I,j} K_I(f_b, f_{b,j})\right] + \epsilon$$7 where the anatomical substrate $$y_t = y_b + \Delta x_t\left[\bar\beta + \sum_{j=1}^N \alpha_{G,j} K_G(g, g_j) + \sum_{j=1}^N \alpha_{C,j} K_C(c, c_j) + \sum_{j=1}^N \alpha_{I,j} K_I(f_b, f_{b,j})\right] + \epsilon$$8 is reconstructed via U-Net from healthy context and $$y_t = y_b + \Delta x_t\left[\bar\beta + \sum_{j=1}^N \alpha_{G,j} K_G(g, g_j) + \sum_{j=1}^N \alpha_{C,j} K_C(c, c_j) + \sum_{j=1}^N \alpha_{I,j} K_I(f_b, f_{b,j})\right] + \epsilon$$9 is a stochastic residual limited to the pathology mask, learned via a diffusion model (Wang et al., 29 Dec 2025). Similarly, Zhang et al. (Generator–Versus–Segmentor) employ an adversarial game where a segmentor accurately detects residual lesions in the generated pseudo-healthy image, enforcing healthiness both at the macroscopic (identity-preserved) and lesion (absence) levels (Zhang et al., 2022). These methods define rigorous metrics, such as A-Dice—measuring lesion suppressibility in the synthetic output—to quantify baseline fidelity.

Adversarial learning frameworks with explicit cycle-consistency (GAN+reconstructor+segmentor), as in Xia et al., enforce that the forward and backward mappings between pathological and pseudo-healthy domains preserve both individual anatomy and lesion structure (Xia et al., 2020). These approaches enable personalized, pathology-free reference images for direct comparison, anomaly localization, and downstream quantification.

6. Clinical Integration and Methodological Considerations

Pathology-free patient-specific baselines concretize the “best-case” specificity and provide actionable references for numerous clinical and algorithmic tasks, including:

• Anchoring evaluation of diagnostic and detection models in rare-event, confounded, or distribution-shifted regimes (Raythatha et al., 10 Feb 2026).
• Enabling interpretable, individualized biomarker construction and radiomic feature selection by direct measurement of deviation from baseline (Chen et al., 17 Mar 2025, Chen et al., 13 Jan 2026).
• Supporting disease trajectory modeling, outlier/anomaly detection, and case-level explanation in medical imaging and genomics (Dalca et al., 2020, Strobl et al., 2022).
• Informing the required domain adaptation and negative-class stratification required for foundation model reliability in clinical settings (Raythatha et al., 10 Feb 2026).

Methodological caveats include the validity of baseline definition (requirement for truly pathology-free control data), the challenge of confounding from non-target abnormalities, and limitations of generative modeling in under-represented anatomical or pathological regimes (Chen et al., 17 Mar 2025, Zhang et al., 2022). Robust negative-class stratification, as well as uncertainty quantification (e.g., via bootstrapped confidence intervals), is recommended to anchor real-world specificity to the pathology-free reference and diagnose failures due to pathologic confounding.

7. Impact and Emerging Directions

The pathology-free patient-specific baseline has become central to current and emerging paradigms in computational translational medicine. Its rigorous deployment facilitates better deconvolution of model specificity loss mechanisms, supports robust benchmarking of generative and discriminative models, and enables truly individualized, interpretable clinical decision-support tools. Methodologies are evolving from fixed, cohort-based references to complex subject-conditioned generative models and causal-inference frameworks, expanding both the range and granularity of pathology-free comparative analysis. As datasets and algorithms scale, maintaining explicit, well-founded definitions of the patient-specific healthy baseline remains critical for safe and effective deployment of AI systems in clinical medicine (Raythatha et al., 10 Feb 2026, Dalca et al., 2020, Strobl et al., 2022, Wang et al., 29 Dec 2025, Chen et al., 13 Jan 2026, Chen et al., 17 Mar 2025).